Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.65 USD
Change Today -0.06 / -2.21%
Volume 362.2K
OHRP On Other Exchanges
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

ohr pharmaceutical inc (OHRP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $12.31
52 Week Low
04/7/15 - $2.48
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ohr pharmaceutical inc (OHRP) Related Bloomberg News

View More Bloomberg News

ohr pharmaceutical inc (OHRP) Related Businessweek News

No Related Businessweek News Found

ohr pharmaceutical inc (OHRP) Details

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes. The company is evaluating OHR-102 eye drops in various Phase II studies for the treatment of retinal diseases, including wet-AMD, retinal vein occlusion, proliferative diabetic retinopathy, and diabetic macular edema. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as steroid induced glaucoma, allergies, and retinal disease. The company is headquartered in New York, New York.

13 Employees
Last Reported Date: 12/22/14

ohr pharmaceutical inc (OHRP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $219.0K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $177.7K
Compensation as of Fiscal Year 2014.

ohr pharmaceutical inc (OHRP) Key Developments

Ohr Pharmaceutical, Inc. - Special Call

To discuss the results from the exploratory phase II IMPACT study evaluating OHR-102 (0.2% squalamine lactate ophthalmic solution) combination therapy for the treatment of the wet form of age-related macular degeneration (wet-AMD)

Ohr Pharmaceutical, Inc. Announces Final Topline Result from OHR-102 Phase II Impact Study

Ohr Pharmaceutical, Inc. announced the topline results from the exploratory Phase II IMPACT study evaluating OHR-102 (0.2% squalamine lactate ophthalmic solution) combination therapy for the treatment of the wet form of age-related macular degeneration (wet-AMD). In the intent-to-treat (ITT-LOCF) population with classic containing choroidal neovascularization (CNV) (OHR-102 n=38, Lucentis® monotherapy n=32), 42% of the patients receiving OHR-102 achieved a =3 line gain at nine months, as compared to 28% in the Lucentis monotherapy group. Less of a benefit was seen in the overall population (classic containing and occult only CNV lesions). The classic containing CNV population represents approximately two thirds of the total wet-AMD population. The positive effect on visual acuity in classic CNV was seen early in the course of treatment and continued to increase through the end of the study, supporting the planned Phase III development program. In patients with classic CNV (ITT-LOCF), mean gains in visual acuity were +10.5 letters for the OHR-102 combination arm and +5.4 letters with Lucentis monotherapy, a clinically meaningful benefit of +5.1 letters. The mean number of injections between the treatment arms, the primary endpoint of the study, was not meaningfully different. The IMPACT study is a nine-month Phase II clinical trial evaluating the safety and efficacy of OHR-102 for the treatment of wet-AMD. The two treatment arms were OHR-102 drops administered twice daily plus Lucentis PRN ("OHR-102" arm or group) versus placebo eye drops administered twice daily plus Lucentis PRN ("Lucentis monotherapy" arm or group). All patients in the study received an initial Lucentis injection. 142 patients were randomized into the study, with 90% of the patients completing the full nine month treatment protocol. The baseline characteristics between the two treatment groups were well balanced. OHR-102 was generally well tolerated, with only two treatment related discontinuations in the study.

Ohr Pharmaceutical Announces Additional Positive Anatomic Data from the OHR-102 Impact Study

Ohr Pharmaceutical, Inc. announced the presentation of new data from the IMPACT study interim analysis at the 38th Annual Macula Society Meeting which took place February 25-28th, in Scottsdale, Arizona. The new data show an early regression of subretinal hyper-reflective material (SHRM), an anatomic biomarker for the wet form of age-related macular degeneration (wet-AMD), which is consistent with the early gains in visual acuity previously reported from this study. The IMPACT study is a nine-month Phase II clinical trial evaluating Squalamine Eye Drops (OHR-102) for the treatment of wet-AMD. Previously announced interim data demonstrated that the combination of OHR-102 plus Lucentis® resulted in a meaningful and clinically relevant improvement in visual acuity compared with Lucentis monotherapy. OHR-102 appeared to have a rapid onset of action, with differences between the combination and control arms observed as early as 4 weeks and continuing to increase at week 12. At the end of the study, patients treated with the combination of OHR-102 plus Lucentis were still improving. The dramatic and early vision gains observed are believed to result in part from the regression of SHRM, which is widely considered to be a combination of neovascular tissue, pre-fibrotic material and other sub retinal exudative and inflammatory debris. The new data presented at the Macula Society Meeting showed that, in a masked analysis of spectral domain optical coherence tomography (OCT) images, the reduction in SHRM occurred early in the study, with differences between the treatment and control groups observed by week 4. The early differences between combination therapy and control groups were observed both in the overall treatment population, as well as in the subset of patients with classic-containing choroidal neovascularization (CNV) lesions, where the difference was even greater. Also presented were new data showing that treatment with OHR-102 appears to prevent further development of SHRM. In those patients treated with the OHR-102 plus Lucentis combination, none experienced worsening in SHRM over the 9 months of the study. In contrast, among Lucentis monotherapy patients, 15% of the overall group and 23% of the classic-containing CNV lesion group experienced worsening of SHRM by the end of the study.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OHRP:US $2.65 USD -0.06

OHRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OHRP.
View Industry Companies

Industry Analysis


Industry Average

Valuation OHRP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OHR PHARMACEUTICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at